Drug Discovery

Can MassiveFold Revolutionize Protein Structure Prediction Speed?
Research & Development Can MassiveFold Revolutionize Protein Structure Prediction Speed?

The quest for faster and more efficient protein structure prediction has taken a significant leap forward with the advent of MassiveFold, a new iteration of AlphaFold designed for parallel processing. Within the realm of molecular biology and drug discovery, the speed and accuracy of protein

How Will Novartis and Schrödinger Transform Drug Discovery Together?
Research & Development How Will Novartis and Schrödinger Transform Drug Discovery Together?

A new partnership between two powerhouses in the pharmaceutical industry promises substantial advancements in drug discovery and development. Novartis, one of the largest pharmaceutical companies globally, will pay Schrödinger $150 million upfront to utilize its advanced computing tools and

Insilico's AI-Developed Drug Shows Promise in Phase IIa IPF Trial
Research & Development Insilico's AI-Developed Drug Shows Promise in Phase IIa IPF Trial

Insilico Medicine, an AI-based drug developer, has made significant strides with its lead candidate, ISM001-055, in the treatment of idiopathic pulmonary fibrosis (IPF). Following promising results from a Phase IIa trial, the company is now gearing up for potentially pivotal clinical trials that

Can Ibuprofen Treat the Rare MAN1B1 Genetic Disorder?
Research & Development Can Ibuprofen Treat the Rare MAN1B1 Genetic Disorder?

Imagine a common over-the-counter pain reliever having the potential to alleviate the symptoms of a rare genetic disorder that currently lacks any formal treatment. This possibility could mark a significant breakthrough for patients who face enormous challenges and discomfort due to their

FDA Approves Aucatzyl, a New CAR-T Therapy to Rival Tecartus
Research & Development FDA Approves Aucatzyl, a New CAR-T Therapy to Rival Tecartus

The recent approval of Aucatzyl by the FDA marks a significant advancement in the treatment landscape for patients with B-cell precursor acute lymphoblastic leukemia, especially those whose disease has progressed following initial chemotherapy treatments. Developed by U.K.-based Autolus

Trump's Return Sparks Uncertainty for Biopharma and Vaccine Sector
Research & Development Trump's Return Sparks Uncertainty for Biopharma and Vaccine Sector

The election of Donald Trump and his return to the White House have sparked significant discussions about the potential impacts on various sectors, particularly the biopharma and vaccine industries. With anticipated shifts in federal policies and key personnel appointments, stakeholders are keenly

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later